{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:55:05Z","timestamp":1785790505555,"version":"3.56.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Sepsis is a systemic inflammatory response syndrome caused by infection, with high incidence and mortality. Therefore, it is necessary to carry out an effective anti-infection treatment. In this work, we designed and synthesized red blood cell (RBC) membrane-coated PLGA nanoparticles named \u03b33-RBCNPs, which target the highly expressed intercellular adhesion molecule-1 (ICAM-1) at the site of infection through the \u03b33 peptide on its surface and kill the <jats:italic>Klebsiella pneumoniae<\/jats:italic> through ciprofloxacin encapsulated in its core. In addition, the homogenous RBC membrane coated on the surface of the nanoparticles helps them avoid immune surveillance and prolong the circulation time of the drug in the body. We found that the \u03b33-RBCNPs target human umbilical vein endothelial cells (HUVECs) activated by TNF-\u03b1 <jats:italic>in vitro<\/jats:italic> and the infected lung of mice in the sepsis model very well. <jats:italic>In vitro<\/jats:italic> evaluation suggested that \u03b33-RBCNPs have a low risk of acute hemolysis and are less likely to be engulfed by macrophages. <jats:italic>In vivo<\/jats:italic> evaluation showed that \u03b33-RBCNPs has a long half-life and good bio-safety. More importantly, we confirmed that \u03b33-RBCNPs have the good antibacterial and anti-infection ability <jats:italic>in vivo<\/jats:italic> and <jats:italic>in vitro<\/jats:italic>. Our research provides a new strategy for the nano-drug treatment of Klebsiella pneumoniae-induced sepsis.<\/jats:p>","DOI":"10.3389\/fmicb.2022.901979","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T09:50:41Z","timestamp":1655373041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Functionalized Erythrocyte Membrane-Coated Nanoparticles for the Treatment of Klebsiella pneumoniae-Induced Sepsis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Rui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.200959","article-title":"Nano-MOFs as targeted drug delivery agents to combat antibiotic-resistant bacterial infections.","volume":"7","author":"Ahmed","year":"2020","journal-title":"R. Soc. Open Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/femsre\/fuy043","article-title":"Klebsiella pneumoniae infection biology: living to counteract host defences.","volume":"43","author":"Bengoechea","year":"2019","journal-title":"FEMS Microbiol. Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1021\/acs.accounts.9b00079","article-title":"Bioinspired and biomimetic nanomedicines.","volume":"52","author":"Chen","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz6980","article-title":"Exosome-based delivery of super-repressor I\u03baB\u03b1 relieves sepsis-associated organ damage and mortality.","volume":"6","author":"Choi","year":"2020","journal-title":"Sci. Adv."},{"key":"B5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis.","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin. Immunopathol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.dci.2019.02.010","article-title":"Microplitis bicoloratus bracovirus modulates innate immune suppression through the eIF4E-eIF4A axis in the insect Spodoptera litura.","volume":"95","author":"Cui","year":"2019","journal-title":"Dev. Comp. Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3238\/arztebl.2018.0345","article-title":"Treatment options for carbapenem- resistant gram-negative infections.","volume":"115","author":"Fritzenwanker","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2017.09.015","article-title":"Nanoparticle-based local antimicrobial drug delivery.","volume":"127","author":"Gao","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial.","volume":"320","author":"Harris","year":"2018","journal-title":"Jama"},{"key":"B10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejpb.2019.09.002","article-title":"Challenges and strategies in drug delivery systems for treatment of pulmonary infections.","volume":"144","author":"Ho","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215376","article-title":"The pathogenesis of sepsis and potential therapeutic targets.","volume":"20","author":"Huang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41551-017-0187-5","article-title":"Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy.","volume":"2","author":"Hussain","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00483","article-title":"Antimicrobial resistance of hypervirulent klebsiella pneumoniae: epidemiology, hypervirulence-associated determinants, and resistance mechanisms.","volume":"7","author":"Lee","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-43969-y","article-title":"Red blood cell membrane bioengineered Zr-89 labelled hollow mesoporous silica nanosphere for overcoming phagocytosis.","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.actbio.2018.07.038","article-title":"Antimicrobial polymers as therapeutics for treatment of multidrug-resistant Klebsiella pneumoniae lung infection.","volume":"78","author":"Lou","year":"2018","journal-title":"Acta Biomater."},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/sur.2017.278","article-title":"Sepsis 2018: definitions and guideline changes.","volume":"19","author":"Napolitano","year":"2018","journal-title":"Surg. Infect."},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2017.17687","article-title":"Enhancing recovery from sepsis: a review.","volume":"319","author":"Prescott","year":"2018","journal-title":"Jama"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.actatropica.2019.04.020","article-title":"Nano-facilitated drug delivery strategies in the treatment of plasmodium infection.","volume":"195","author":"Puttappa","year":"2019","journal-title":"Acta Trop."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20198595","article-title":"Sepsis: evolving concepts and challenges.","volume":"52","author":"Salom\u00e3o","year":"2019","journal-title":"Braz. J. Med. Biol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/jam.13533","article-title":"Biofilm formation and antibiotic resistance in Klebsiella pneumoniae urinary strains.","volume":"123","author":"Vuotto","year":"2017","journal-title":"J. Appl. Microbiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.34133\/2020\/3676954","article-title":"Leukocyte membrane-coated liquid metal nanoswimmers for actively targeted delivery and synergistic chemophotothermal therapy.","volume":"2020","author":"Wang","year":"2020","journal-title":"Research"},{"key":"B22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.mib.2018.04.004","article-title":"Klebsiella pneumoniae as a key trafficker of drug resistance genes from environmental to clinically important bacteria.","volume":"45","author":"Wyres","year":"2018","journal-title":"Curr. Opin. Microbiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jconrel.2020.02.030","article-title":"Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis.","volume":"321","author":"Yang","year":"2020","journal-title":"J. Cont. Rel."},{"key":"B24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.4155\/tde-2018-0009","article-title":"Recent advances in nanomedicine for sepsis treatment.","volume":"9","author":"Yuk","year":"2018","journal-title":"Ther. Deliv."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803618","article-title":"Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management.","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.901979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T09:50:44Z","timestamp":1655373044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.901979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":25,"alternative-id":["10.3389\/fmicb.2022.901979"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.901979","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"901979"}}